Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Parallel Group Phase 4 Study to Determine Progression-Free Survival and Evaluate Patient Experience for Patients With Metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC) Treated With ALK Inhibitors

Next Previous
X
Search
Trial Profile

An Observational Parallel Group Phase 4 Study to Determine Progression-Free Survival and Evaluate Patient Experience for Patients With Metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC) Treated With ALK Inhibitors

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary) ; Alectinib; Anaplastic lymphoma kinase inhibitors; Ceritinib; Lorlatinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology

    • Most Recent Events

    • 29 Nov 2023 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2022 According to ClinicalTrials.gov record, protocol has been amended as time frame of primary endpoint changed from 36 months to 24 months and so the other endpoint timeframe changes from 36 months to 24 months .
    • 27 May 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top